Research graph
References from Outcome Prediction After [ 177 Lu]Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: External Validation of a [ 68 Ga]Ga-PSMA-11 PET–Based Model with [ 18 F]F-Flotufolastat. Local targets link to admitted publications; unresolved targets remain external evidence.
10.2967/jnumed.116.173757
10.2967/jnumed.116.173757 · External reference
Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer
10.1016/j.eururo.2018.11.016 · 2019 · External reference
10.1016/s1470-2045(18)30198-0
10.1016/s1470-2045(18)30198-0 · External reference
10.1016/s0140-6736(21)00237-3
10.1016/s0140-6736(21)00237-3 · External reference
10.1056/nejmoa2107322
10.1056/nejmoa2107322 · External reference
Initial clinical experience with 177Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial
10.3389/fonc.2024.1483953 · 2024 · External reference
10.1016/s1470-2045(21)00274-6
10.1016/s1470-2045(21)00274-6 · External reference
18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging
10.7150/thno.37894 · 2020 · External reference
Unresolved reference
External reference
Prognostic 18F-flotufolastat PET parameters for outcome assessment of 177Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer
10.1007/s00259-024-07003-2 · 2025 · External reference
10.2967/jnumed.122.265346
10.2967/jnumed.122.265346 · External reference
10.2967/jnumed.119.234922
10.2967/jnumed.119.234922 · External reference
Quantitative implications of the updated EARL 2019 PET-CT performance standards
10.1186/s40658-019-0257-8 · 2019 · External reference
10.1200/jco.2015.64.2702
10.1200/jco.2015.64.2702 · External reference
Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting
10.1007/s00259-021-05497-8 · 2022 · External reference
10.2967/jnumed.120.261863
10.2967/jnumed.120.261863 · External reference
10.2967/jnumed.117.198119
10.2967/jnumed.117.198119 · External reference
10.1002/sim.6787
10.1002/sim.6787 · External reference
Unresolved reference
External reference
10.1016/0197-2456(96)00075-x
10.1016/0197-2456(96)00075-x · External reference
10.1001/jama.1982.03320430047030
10.1001/jama.1982.03320430047030 · External reference
10.1002/sim.4780030207
10.1002/sim.4780030207 · External reference
Unresolved reference
External reference
Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
10.1016/j.eclinm.2024.102862 · 2024 · External reference
Prognostic value of the De Ritis ratio for overall survival in patients with metastatic castration-resistant prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy
10.3390/cancers15204907 · 2023 · External reference
Normal-organ distribution of PSMA-targeting PET radiopharmaceutical 18F-flotufolastat: a post hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies
10.62347/incg3525 · 2024 · External reference
Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution
10.1186/s40644-019-0211-y · 2019 · External reference
Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy
10.1186/s13550-024-01190-7 · 2025 · External reference
10.2967/jnumed.121.262713
10.2967/jnumed.121.262713 · External reference
SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T
10.1007/s00259-023-06281-6 · 2023 · External reference
10.1016/s1470-2045(22)00605-2
10.1016/s1470-2045(22)00605-2 · External reference
10.1148/radiol.233460
10.1148/radiol.233460 · External reference
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
10.1016/s1470-2045(25)00339-0 · 2025 · External reference
Response evaluation criteria in PSMA PET/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer
10.1148/radiol.222148 · 2023 · External reference
10.2967/jnumed.124.267723
10.2967/jnumed.124.267723 · External reference
